These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27036356)

  • 21. Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry.
    O'Brien S
    Br J Clin Pharmacol; 2015 Feb; 79(2):168-72. PubMed ID: 25601037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization.
    Outterson K; Rex JH
    Transl Res; 2020 Jun; 220():182-190. PubMed ID: 32165059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of public-private partnerships in addressing the biomedical innovation challenge.
    Said M; Zerhouni E
    Nat Rev Drug Discov; 2014 Nov; 13(11):789-90. PubMed ID: 25359362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pay drug companies $1bn for each new antibiotic, says report.
    Owen J
    BMJ; 2016 May; 353():i2863. PubMed ID: 27198868
    [No Abstract]   [Full Text] [Related]  

  • 25. Innovation of novel antibiotics: an economic perspective.
    McKellar MR; Fendrick AM
    Clin Infect Dis; 2014 Oct; 59 Suppl 3():S104-7. PubMed ID: 25261536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.
    Kostyanev T; Bonten MJ; O'Brien S; Steel H; Ross S; François B; Tacconelli E; Winterhalter M; Stavenger RA; Karlén A; Harbarth S; Hackett J; Jafri HS; Vuong C; MacGowan A; Witschi A; Angyalosi G; Elborn JS; deWinter R; Goossens H
    J Antimicrob Chemother; 2016 Feb; 71(2):290-5. PubMed ID: 26568581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (Inter)nationalising the antibiotic research and development pipeline.
    Singer AC; Kirchhelle C; Roberts AP
    Lancet Infect Dis; 2020 Feb; 20(2):e54-e62. PubMed ID: 31753765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
    Towse A; Hoyle CK; Goodall J; Hirsch M; Mestre-Ferrandiz J; Rex JH
    Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A New Product Development Partnership Model for Antibiotic Resistance.
    Billington JK
    Am J Law Med; 2016 May; 42(2-3):487-523. PubMed ID: 29086636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stimulating antibiotic development.
    Tillotson G
    Lancet Infect Dis; 2010 Jan; 10(1):2-3. PubMed ID: 20129141
    [No Abstract]   [Full Text] [Related]  

  • 32. Preserving the 'commons': addressing the sustainable use of antibiotics through an economic lens.
    Morel CM; Edwards SE; Harbarth S
    Clin Microbiol Infect; 2017 Oct; 23(10):718-722. PubMed ID: 28811243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone.
    Hollis A
    Appl Health Econ Health Policy; 2024 Mar; 22(2):155-164. PubMed ID: 38133844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives.
    Morel CM; Edwards SE
    J Law Med Ethics; 2018 Jun; 46(1_suppl):75-80. PubMed ID: 30146962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others.
    Bettiol E; Hackett J; Harbarth S
    J Law Med Ethics; 2018 Jun; 46(1_suppl):5-8. PubMed ID: 30146955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of antibiotic restrictions: the pharmaceutical perspective.
    Power E
    Clin Microbiol Infect; 2006 Aug; 12 Suppl 5():25-34. PubMed ID: 16827822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new prize system for drug innovation.
    Gandjour A; Chernyak N
    Health Policy; 2011 Oct; 102(2-3):170-7. PubMed ID: 21724290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. R&D: Antibiotic partners promote discovery.
    Bakken JS
    Nature; 2016 Sep; 537(7619):167. PubMed ID: 27604939
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.